Table 4.

Overall and BMI-stratified comparison of Ki67, p4E-BP1 and pAkt between benign/hyperplasia versus atypia/carcinoma

	Benign/hyperplasia	Atypia/carcinoma	P
All cases combined	n=18	n=25
BMI	35.4 (25.8–41.7)	34.4 (26.9–45.5)	0.703
Ki67	0 (0–20)	50 (40–80)	<0.001
Cytoplasmic pAkt	150 (0–200)	175 (100–200)	0.254
Nuclear pAkt	190 (100–250)	190 (150–200)	0.852
Cytoplasmic p4E-BP1	0 (0–20)	95 (30–180)	0.001
Nuclear p4E-BP1	70 (10–100)	170 (95–195)	0.003
Obese	n=11	n=18
BMI	40.4 (35.8–45.8)	38.5 (34.4–52.9)	0.928
Ki67	10 (5–20)	50 (30–80)	<0.001
Cytoplasmic pAkt	70 (0–190)	180 (10–200)	0.117
Nuclear pAkt	150 (100–250)	200 (180–210)	0.425
Cytoplasmic p4E-BP1	0 (0–10)	95 (30–180)	0.001
Nuclear p4E-BP1	65 (20–100)	180 (100–200)	0.002
Nonobese	n=7	n=7
BMI	25.8 (23.9–27.0)	23.6 (20.1–25.9)	0.370
Ki67	20 (0–30)	50 (40–80)	0.008
Cytoplasmic pAkt	180 (0–200)	100 (100–190)	0.652
Nuclear pAkt	200 (100–200)	150 (120–190)	0.335
Cytoplasmic p4E-BP1	0 (0–90)	0 (0–30)	0.543
Nuclear p4E-BP1	100 (50–140)	105 (60–190)	0.389

Note: The values are expressed as median (interquartile range).

Abbreviations: BMI, body mass index; p4E-BP1, phosphorylated eukaryotic initiation factor 4E binding protein-1; pAkt, phosphorylated Akt.